Chinese Journal of Organic Chemistry ›› 2023, Vol. 43 ›› Issue (2): 763-770.DOI: 10.6023/cjoc202206048 Previous Articles     Next Articles

3-芳基-2-亚胺-苯并[e]-1,3-噁嗪-4-醇衍生物的合成及活性评价

廖楚婕a,b, 阮洪瑶a,b, 姜峻峰a,b, 罗伦a,b,*(), 胡扬根a,b,*()   

  1. a 湖北医药学院药学院 湖北十堰 442000
    b 湖北医药学院 武当特色中药研究湖北省重点实验室 湖北十堰 442000
  • 收稿日期:2022-07-27 修回日期:2022-08-23 发布日期:2022-10-10
  • 基金资助:
    国家自然科学基金(81773746); 湖北医药学院“十四五”省级优势特色学科群(生物与医药)2022年(2022BMXKQY7); 湖北医药学院人才启动金资助计划(2018QDJZR13); 湖北医药学院大学生创新创业训练计划(Nos. 202110929006, S202110929008和YSRTP202104(202110929006); 湖北医药学院大学生创新创业训练计划(Nos. 202110929006, S202110929008和YSRTP202104(S202110929008); 湖北医药学院大学生创新创业训练计划(Nos. 202110929006, S202110929008和YSRTP202104(YSRTP202104)

Synthesis and Activity Evaluation of 3-Aryl-2-imino-benzo[e][1,3]-oxazin-4-ol Derivatives

Chujie Liaoa,b, Hongyao Ruana,b, Junfeng Jianga,b, Lun Luoa,b(), Yanggen Hua,b()   

  1. a School of Pharmaceutical Sciences, Hubei University of Medicine, Shiyan, Hubei 442000
    b Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Hubei University of Medicine, Shiyan, Hubei 442000
  • Received:2022-07-27 Revised:2022-08-23 Published:2022-10-10
  • Contact: *E-mail: luolun@hbmu.edu.cn;huyg@hbmu.edu.cn
  • Supported by:
    National Natural Science Foundation of China(81773746); Advantages Discipline Group (Biology and Medicine) Project in Higher Education of Hubei Province (2021-2025(2022BMXKQY7); Cultivating Project for Young Scholar at Hubei University of Medicine(2018QDJZR13); Innovative Research Program for College Students of Hubei University of Medicine(202110929006); Innovative Research Program for College Students of Hubei University of Medicine(S202110929008); Innovative Research Program for College Students of Hubei University of Medicine(YSRTP202104)

Benzoxazines are important heterocycles bearing remarkable biological activities, which widely used in medicine, pesticide and other fields. In this study, 3-aryl-2-imino-benzo[e][1,3]-oxazin-4-ol derivatives 4a~4k were efficiently synthesized by aza-Wittig tandem reaction with simple and easy materials under mild conditions, and their structures were confirmed by 1H NMR, 13C NMR and HRMS. X-Ray structure analysis of diethyl (Z)-2-((4-hydroxy-3-phenyl-3,4-dihydro-2H-benzo[e]- [1,3]oxazin-2-ylidene)amino)-5-methylfuran-3,4-dicarboxylate (4a) verified that the carbon-nitrogen (C=N) assigned Z-configuration to the compound structure. In vitro, the antitumor activities of compounds 4a~4k were analyzed with CCK8 standard method. The results indicated that most of the compounds showed potential antitumor activities. Among them, the inhibitory rate of the most active compound diethyl (Z)-2-((4-hydroxy-6-methyl-3-phenyl-3,4-dihydro-2H-benzo[e][1,3]oxa- zin-2-ylidene)amino)-5-methyl-furan-3,4-dicarboxylate (4e) against HepG2 and HeLa cell lines at the concentration of 0.01 mg/mL were 45.83% and 42.76%, respectively, which were weaker than the commercial gefitinib. Furthermore, their antioxidant properties were detected via 1,1-diphenyl-2-picrylhydrazyl (DPPH) free radical scavenging assay. The results showed that the IC50 values of free radical scavenging rates of diethyl (Z)-2-((4-hydroxy-3-phenyl-3,4-dihydro-2H-benzo[e][1,3]oxazin- 2-ylidene)amino)-5-methylfuran-3,4-dicarboxylate (4d), 4e and diethyl (Z)-2-((6,8-dichloro-4-hydroxy-3-phenyl-3,4-dihydro- 2H-benzo[e][1,3]oxazin-2-ylidene)amino)-5-methylfuran-3,4-dicarboxylate (4j) were 0.294, 0.255 and 0.338 mmol/L, respectively, which slightly higher than that of the control ascorbic acid.

Key words: benzo[e][1,3]oxazin-4-ol, synthesis, aza-Wittig reaction, antitumor, antioxidant